RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 No Significant Benefit with Rosiglitazone in Preventing Progression of Atherosclerosis in Diabetic Patients with a History of Cardiovascular Disease
JF MD Conference Express
YR 2009
FD SAGE Publications
VO 8
IS 8
SP 21
OP 22
DO 10.1177/155989770900800813
UL http://mdc.sagepub.com/content/8/8/21.abstract
AB Thiazolidinediones, such as rosiglitazone, have been shown to increase insulin sensitivity and reduce other cardiovascular risk factors but increase fluid retention and the risk of heart failure. This article discusses results of the Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients with Cardiovascular History [APPROACH; NCT00116831] trial.